Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
| Autor Principal: | |
|---|---|
| Outros autores: | |
| Formato: | Thesis |
| Idioma: | English |
| Publicado: |
Brac University
2024
|
| Subjects: | |
| Acceso en liña: | http://hdl.handle.net/10361/23694 |
| id |
10361-23694 |
|---|---|
| record_format |
dspace |
| spelling |
10361-236942024-07-15T21:04:08Z Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis Rahman, Sanjida Jamiruddin, Mohd. Raeed School of Pharmacy, Brac University Chemotherapy Biliary tract cancer Cancer therapy Immunotherapy Medical oncology Biliary tract--Cancer Gallbladder--Cancer This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 28-33). Introduction: The utilization of chemotherapy treatment (CT) in the context of biliary tract cancers (BTC) remains a subject of considerable debate. To date, no comprehensive efficacy assessment has been conducted to directly compare the outcomes of chemotherapy (CT) in the patient population. It is worth noting that recent years have witnessed notable advancements in chemotherapy interventions for BTC. However, it is imperative to underscore that further research and investigation are necessary to comprehensively understand the full scope of treatment options and their relative effectiveness in addressing this challenging disease. Method: We searched the databases of PubMed, Biomed, Scholarly, and The Cochrane Library to find published publications that were relevant. We selected RCTs with patients with BTC undergoing adjuvant chemotherapy for our systematic analysis, which covered publications from 2010 to 2022. Indirect comparisons of overall survival (OS), progression-free survival (PFS), severe adverse events (SAE), and overall adverse events (OAE) were conducted using meta-analysis methods. Different chemotherapy treatments were selected. We employed a random-effects model for aggregating the data. Result: A total of 4395 individuals from 18 trials were examined, all of whom got the chemotherapy of our choosing. The findings of the indirect comparison showed that there was no discernible increase in overall survival for either Capecitabine plus Gemcitabine plus Oxaliplatin or Gemcitabine plus Cisplatin. The hazard ratios (hrs) for each combination were 1.69 [95% (CI): 1.17 to 2.44, 1.92 [95% (CI): 0.98 to 3.77, and 0.93 [95% (CI): 0.69 to 1.25], respectively. Likewise, there was no discernible increase in PFS among the three distinct medication categories under scrutiny. Despite this, gemcitabine + oxaliplatin continues to be more effective. Conclusion: We did not find any statistically significant improvements in OS or PFS for any of the three medication groups in the current analysis. Because of its better effectiveness, gemcitabine + oxaliplatin can be regarded the standard of therapy in the adjuvant scenario until more prospective studies are completed. Sanjida Rahman B. Pharmacy 2024-07-15T04:26:25Z 2024-07-15T04:26:25Z ©2024 2024-02 Thesis ID 18346027 http://hdl.handle.net/10361/23694 en 46 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Chemotherapy Biliary tract cancer Cancer therapy Immunotherapy Medical oncology Biliary tract--Cancer Gallbladder--Cancer |
| spellingShingle |
Chemotherapy Biliary tract cancer Cancer therapy Immunotherapy Medical oncology Biliary tract--Cancer Gallbladder--Cancer Rahman, Sanjida Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. |
| author2 |
Jamiruddin, Mohd. Raeed |
| author_facet |
Jamiruddin, Mohd. Raeed Rahman, Sanjida |
| format |
Thesis |
| author |
Rahman, Sanjida |
| author_sort |
Rahman, Sanjida |
| title |
Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| title_short |
Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| title_full |
Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| title_fullStr |
Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| title_full_unstemmed |
Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| title_sort |
clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23694 |
| work_keys_str_mv |
AT rahmansanjida clinicaloutcomesandsafetycomparisonofgemcitabinepluscisplatincapecitabinemonotherapyandgemcitabineplusoxaliplatininthemanagementofgallbladdercarcinomaacomprehensivemetaanalysis |
| _version_ |
1814309388524978176 |